Testosterone Undecanoate for Prostate Cancer
This trial will analyze the effects of oral testosterone therapy given on a schedule of seven days of therapy followed by seven days of no therapy for a 28 day cycle in men with metastatic castrate resistant prostate cancer.
- Metastatic Castration Resistant Prostate Cancer
- Prostate Cancer
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Is enrollment available for this experiment at the moment?
"According to clinicaltrials.gov, this medical trial is presently accepting participants. It was initially posted on March 7th 2022 and the details were most recently modified on May 6th of the same year."
In what type of medical conditions is Testosterone Undecanoate commonly prescribed?
"Testosterone Undecanoate is a viable therapeutic option for treating hypogonadotropic hypogonadism, castration-associated syndromes, and hypergonadotropic hypogonadism."
What potential risk factors are associated with Testosterone Undecanoate?
"Testosterone Undecanoate has had prior safety data collected, granting it a score of 2. Thus far, there have been no studies which demonstrate efficacy in this field."
Are there any previous investigations involving Testosterone Undecanoate?
"Presently, 105 clinical trials researching Testosterone Undecanoate are being conducted, 30 of which are in the third phase. While Germantown, Tennessee is home to many of these investigations, 5783 sites across the world have studies for this medication running too."
How many participants are engaged in this clinical trial?
"Indeed, the research hosted on clinicaltrials.gov indicates that this medical trial started recruiting participants on March 7th 2022 and is still actively doing so. The team needs to enroll thirty individuals across one site."